FDA Approves Medafor's Unique Hemostatic Technology
Minneapolis, Minn., December 2001 - Medafor, Inc., announced today that the company has received regulatory clearance from the Food and Drug Administration (FDA) to market its breakthrough technology as a topical hemostat for the local management of bleeding wounds. READ FULL STORY.

Medafor, Inc., Appoints Price Waterhouse Coopers to Support Operations
Minneapolis, Minn., August 2001 - Medafor, Inc., is pleased to announce that an agreement has been reached with PricewaterhouseCoopers to provide independent financial services in support of the company's escalating market position.

Medafor, Inc., Adds Two Management Team Members
Minneapolis, Minn., June 7, 2001 - Medafor, Inc., is pleased to announce the addition of two members to its management team. READ FULL STORY.

Hemadex Technology Studies Presented at NATA Symposium
Minneapolis, Minn., April 2001 - Medafor, Inc., is proud to announce that its MPH™ (Microporous Polysaccharide Hemospheres) technology was the subject of two studies presented at the Network for Advancement of Transfusion Alternatives (NATA) Symposium last month in Berlin. READ FULL STORY.